Internal Medicine, Gastroenterology · Weymouth, MA
NPI
1801822564
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
90 Libbey Industrial Pkwy Ste 101
Weymouth, MA, 02189
Phone (617) 421-1091
Groups this clinician bills Medicare through
Medicare paid, 2024
$144K
721 services
Medicare patients, 2024
307
Average age 73
Drug cost, 2024
$214K
794 prescriptions
Company payments, 2025
$1,625
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel S Mishkin was code 45380 (lower gi endoscopy - other), 124 times for 124 patients. In total Daniel S Mishkin billed 721 services in 63 codes, and Medicare paid $144K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-02-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 45380 Lower GI Endoscopy - Other | Office | 124 | 124 | $173.85 | $22K |
| 99215 Office E&M - Established | Office | 104 | 72 | $144.83 | $15K |
| 45385 Colonoscopy - Lesion Removal | Office | 93 | 93 | $388.53 | $36K |
| 43239 Upper GI Endoscopy | Office | 68 | 66 | $187.81 | $13K |
| 36415 Venipuncture Blood Collection | Office | 35 | 27 | $8.65 | $303 |
| 43251 Upper GI Endoscopy | Office | 25 | 25 | $398.73 | $9,968 |
| 45380 Lower GI Endoscopy - Other | Facility | 22 | 22 | $72.95 | $1,605 |
| 99214 Office E&M - Established | Office | 22 | 21 | $101.11 | $2,224 |
| 85025 Blood Count | Office | 21 | 18 | $7.61 | $160 |
| 80053 Clinical Chemistry | Office | 16 | 15 | $10.35 | $166 |
| 45330 Lower GI Endoscopy - Other | Office | 16 | 16 | $164.95 | $2,639 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Office | 15 | 15 | $313.94 | $4,709 |
| 91110 Standard X-ray | Office | 14 | 14 | $658.63 | $9,221 |
| 45385 Colonoscopy - Lesion Removal | Facility | 13 | 13 | $208.44 | $2,710 |
| 43249 Upper GI Endoscopy | Office | 12 | 11 | $995.30 | $12K |
By year: 2022 $143K for 796 services; 2023 $155K for 760 services; 2024 $144K for 721 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 35 | 27 | $8.65 | $303 |
| 85025 Blood Count | 21 | 18 | $7.61 | $160 |
| 80053 Clinical Chemistry | 16 | 15 | $10.35 | $166 |
Medicare prescription drug claims, 2024
In 2024, the drug Daniel S Mishkin prescribed most often to Medicare patients was Omeprazole, with 165 prescriptions and refills. In total Daniel S Mishkin wrote 794 Medicare prescriptions that cost $214K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Omeprazole Generic | 165 | 416 | 58 | $3,392 |
| Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl | 93 | 93 | 91 | $1,675 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 91 | 91 | 88 | $6,272 |
| Peg3350-Sod Sul-Nacl-Kcl-Asb-C Peg3350/Sod Sul/Nacl/Kcl/Asb/C | 72 | 72 | 66 | $4,719 |
| Pantoprazole Sodium Generic | 46 | 118 | 18 | $905 |
| Famotidine Generic | 33 | 77 | 11 | $342 |
| Linzess Linaclotide | 32 | 32 | Under 11 | $17K |
| Mesalamine Generic | 30 | 60 | Under 11 | $12K |
| Amitriptyline Hcl Generic | 24 | 30 | Under 11 | $166 |
| Colestipol Hcl Generic | 16 | 20 | Under 11 | $1,131 |
| Ondansetron Hcl Generic | 13 | 13 | 12 | $12.51 |
| Budesonide Ec Budesonide | 13 | 17 | Under 11 | $910 |
| Ursodiol Generic | 11 | 11 | Under 11 | $817 |
Brand drugs: - claims; generic drugs: 668 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel S Mishkin $1,625 ($500 in general payments such as food, travel and fees and $1,125 for research) from 3 companies. The largest payer was Sanofi US Services Inc. with $1,625.
| Company | Payments | Amount |
|---|---|---|
| Sanofi US Services Inc. SNY | 4 | $1,625 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.